

Phase II class routine

	9-10am	10-11am	11-1.30 Clinical posting	1.30- 2.30 pm reces s	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 3/5/21	L1 IM1.1 heart diseases RHD,CAD	L1 CM7.1 Epidemiolog y concept			P1 PA23.1 Urine examinati on A	P1 PH1.3 Drug formulation, delivery B	P1 MI1.1 Microscopy C
Tues 4/5/21	L1 MI1.1 Introductio n, history	L1 PH1.1, 1.9 Drug nomenclatur e			C	A	B
Wed 5/5/21	L1 PA1.1,1.2,1 .3 History common diseases	L2 PH1.2,1.3 EBM, TDM, Drug formulations			B	C	A
Thurs 6/5/21	L1 SU1.1 response to injury	L2 PA2.1,2.2 Cell injury			P2 PA23.1 A	P2 PH1.3 B	P2 MI1.2 C
Fri 7/5/21	AETCOM	L2 MI1.1 Bacteria morphology			C	A	B
Sat 8/5/21	L3 PH1.11 Drug administrat ion	L3 PA2.4,2.7 Cell death, apoptosis			B	C	A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30 pm rece ss	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM

Mon 10/5/21	L2 IM1.1 heart diseases RHD,CAD	L3 MI1.1 Bacterial genetics			P3 PA23.2 Body fluid A	P3 PH1.9 Nomenclature B	P3 MI1.1 Taxonomy SGD C
Tues 11/5/21	L4 MI1.6 Antimicrobial resistance	L4 PH1.42,1.43 Chemotherapy principles			C	A	B
Wed 12/5/21	L4 PA2.3,2.5 Gangrene, calcification	L5 PH1.42,1.43 Chemotherapy principles			B	C	A
Thurs 13/5/21	L2 SU1.2,1.3 response to injury	L5 PA2.6 Cellular adaptation			P4 PA23.3 Semen analysis , TFT A	P4 PH1.10 Prescription rationality B	P4 MI1.1 Bacteria morphology C
Fri 14/5/21							
Sat 15/5/21							

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 17/5/21	L3 IM1.3 RHD Infective Endocarditis	L2 CM7.5 Descriptive statistics			P5 PA23.3 Cytology, staining A	P5 PH1.10 Prescription criticism B	P5 MI8.9,8.10 Specimen collection Transport C
Tues 18/5/21	L5 MI1.1 bacterial infection	L6 PH1.10 Prescription writing			P4 PA23.3 Semen analysis, TFT C	P4 PH1.10 Prescription rationality A	P4 MI1.1 Bacteria morphology B
Wed 19/5/21	L6 PA3.1 Amyloidosis	L7 PH1.4 Absorbtion, distribution			P4 PA23.3 Semen analysis, TFT B	P4 PH1.10 Prescription rationality C	P4 MI1.1 Bacteria morphology A
Thurs 20/5/21	L3 SU3.1 blood components	L7 PA4.1,4.2 Acute inflammation			P6 PA23.3 LFT A	P6 PH1.11 Routes drug administration B	P6 MI1.2 Staining technique C
Fri 21/5/21	AETCOM	MI1.1 Overview bact infectn			P5 PA23.3 Cytology, staining C	P5 PH1.10 Prescription criticism A	P5 MI8.9,8.10 Specimen collection Transport B
Sat 22/5/21	L8 PH1.4 Metabolism, excretion	L8 PA 4.3 chronic Inflammation			P5 PA23.3 Cytology, staining B	P5 PH1.10 Prescription criticism C	P5 MI8.9,8.10 Specimen collection Transport A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 24/5/21	L4 IM1.4,1.5 1.6 HF	L7 MI1.1 virology			P7 PA2.8 Cell injury A	P7 PH2.1 Dosage forms B	P7 MI1.2 Gram staining C
Tues 25/5/21	L8 MI1.1 parasitology	L9 PH1.5 Drug action			P6 PA23.3 LFT C	P6 PH1.11 Routes drug administration A	P6 MI1.2 Staining technique B
Wed 26/5/21							
Thurs 27/5/21	L4 SU3.2,3.3 blood components	L9 PA5.1 Repair & regeneraion			P8 PA3.2 Amyloidosis A	P8 PH2.2 ORS B	P8 MI1.1 Culture media(SGD) C
Fri 28/5/21	L1 FM1.1,1.2 history introduction	L9 MI1.1 mycology			P7 PA2.8 Cell injury C	P7 PH2.1 Dosage forms A	P7 MI1.2 Gram staining B
Sat 29/5/21	L10 PH1.5 DRUG ACTION	L10 PA6.1,6.2 Oedema, congestion			P6 PA23.3 LFT B	P6 PH1.11 Routes drug administration C	P6 MI1.2 Staining technique A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 31/5/21	L5 IM1.7,1.8 Arrythmia in HF	L3 CM7.5 Case control study			P9 PA4.4 Acute inflammation A	P9 PH1.6,1.7 ADR Pvigilance B	P9 MI1.6,1.1 Lab diag bacterial inf(SGD) C
Tues 1/6/21	L10 MI1.3 Epidemiology infectious dis	L11 PH1.7 ADR			P8 PA3.2 Amyloidosis C	P8 PH2.2 ORS A	P8 MI1.1 Culture media(SGD) B
Wed 2/6/21	L11 PA6.3 Shock	L12 PH1.6 ADR reporting Pvigilance			P7 PA2.8 Cell injury B	P7 PH2.1 Dosage forms C	P7 MI1.2 Gram staining A
Thurs 3/6/21	L5 SU2.1 shock	L12 PA6.4 thrombosis			P10 PA4.4 Chronic inflammation A	P10 PH1.6,1.7 ADR B	P10 MI1.1 Bacterial inf. Patho C (SGD)
Fri 4/6/21	AETCOM	L11 MI1.1 Inert acquired immunity			P9 PA4.4 Acute inflammation C	P9 PH1.6,1.7 ADR Pvigilance A	P9 MI1.6,1.1 Lab diag bacterial inf(SGD) B
Sat 5/6/21	L13 PH1.8 drug interaction	L13 PA6.5,6.6 embolism, ischaemia			P8 PA3.2 Amyloidosis B	P8 PH2.2 ORS C	P8 MI1.1 Culture media(SGD) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 7/6/21	L6 IM1.9 Acute rheumatic fever	L12 MI1.8 antibody			P11 PA6.7 infarction	P11 PH3.4 ADR reporting	P11 MI1.1 Viral lab diag
Tues 8/6/21	L13 MI1.8 Ag- Ab reaction	L14 PH1.12, 1.56 dose calculation			P10 PA4.4 Chronic inflammation	P10 PH1.6,1.7 ADR	P10 MI1.1 Bacterial inf. Patho (SGD)
Wed 9/6/21	L14 PA7.1,7.2 neoplasia	L15 PH1.14 Cholinergic drugs			P9 PA4.4 Acute inflammation	P9 PH1.6,1.7 ADR Pvigilance	P9 MI1.6,1.1 Lab diag bacterial inf(SGD)
Thurs 10/6/21	L6 SU2.2,2.3 shock	L15 PA7.3 carcinogens			P12 PA8.3 diagnostic cytology	P12 PH2.4 Dose calculation	P12 MI1.2 Stool microscopy
Fri 11/6/21	L2 FM1.3 I.P.C,inquest Cr.P.C	L14 MI1.8 Ag- Ab reaction			P11 PA6.7 infarction	P11 PH3.4 ADR reporting	P11 MI1.1 Viral lab diag
Sat 12/6/21	L16 PH1.14 anticholinergic	L16 PH7.4,7.5 Tumour immunology			P10 PA4.4 Chronic inflammation	P10 PH1.6,1.7 ADR	P10 MI1.1 Bacterial inf. Patho (SGD)

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 14/6/21	L7 IM1.21 Ac & Subacute (Bac) endo carditis	L4 CM7.5 Cohort study			P13 PA8.3 Cytology A	P13 PH1.12 dose calculation B	P13 MI1.1,1.2 fungal lab diag C
Tues 15/6/21	L15 MI1.8 complement	L17 PH1.14 adrenergic drug			P12 PA8.3 diagnostic cytology C	P12 PH2.4 Dose calculation A	P12 MI1.2 Stool microscopy B
Wed 16/6/21	L17 PA8.1,8.2 cytology	L18 PH1.14 antiadrenergic drug			P11 PA6.7 Infarction B	P11 PH3.4 ADR reporting C	P11 MI1.1 Viral lab diag A
Thurs 17/6/21	L7 SU4.1,4.2 Burn	L18 PA9.1,9.2 immunity hypersensitivity			P14 PA13.2 Anticoagulants A	P14 PH2.3 i.v setting B	P14 MI1.1 Normal human flora (SGD) C
Fri 18/6/21	AETCOM	L16 MI1.8 components of immune system			P13 PA8.3 Cytology C	P13 PH1.12 dose calculation A	P13 MI1.1,1.2 fungal lab diag B
Sat 19/6/21	L19 PH1.14 sk muscle relaxant	L19 PH9.4,9.5,9.7 autoimmunity disorders			P12 PA8.3 diagnostic cytology B	P12 PH2.4 Dose calculation C	P12 MI1.2 Stool microscopy A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 21/6/21	L8 IM4.1,2,3 host immune status, febrile response	L17 MI1.8 immune system components			P15 PA13.2 anticoagulant	P15 PH1.8 drug interaction	P15 MI1.8,8.15 Ag-Ab reaction
Tues 22/6/21	L18 MI1.8 immune response	L20 PH1.17 local anaesthesia			P14 PA13.2 anticoagulants	P14 PH2.3 i.v setting	P14 MI1.1 Normal human flora (SGD)
Wed 23/6/21	L20 PA9.3 HLA	L21 PH1.18 General anaesthesia			P13 PA8.3 cytology	P13 PH1.12 dose calculation	P13 MI1.1,1.2 fungal lab diag
Thurs 24/6/21	L8 SU4.3,4.4 Burn	L21 PA9.6 HIV/AIDS			P16 PA13.5 PBS Anaemia	P16 PH1.8 Drug interaction	P16 MI1.2 Acid fast staining
Fri 25/6/21	L3 FM1.4,1.5 summons, witness, courts	L19 MI1.8 immune response			P15 PA13.2 anticoagulant	P15 PH1.8 drug interaction	P15 MI1.8,8.15 Ag-Ab reaction
Sat 26/6/21	L22 PH1.16 antihistaminics	L22 PA10.4 Common infections			P14 PA13.2 anticoagulants	P14 PH2.3 i.v setting	P14 MI1.1 Normal human flora (SGD)

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 28/6/21	L9 IM1.24,1.25 drugs for HF surgical intervention	CM7.5 experimental study			P17 PA13.5 PBS Anaemia A	P17 PH1.8 drug interaction B	P17 MI1.8 Acid fast staining C
Tues 29/6/21	L20 MI2.7 HIV/AIDS	L23 PH1.16 5HT related drugs			P16 PA13.5 PBSAnaemia C	P16 PH1.8 Drug interaction A	P16 MI1.2 Acid fast staining B
Wed 30/6/21	L23 PA10.1,2.3 malaria, leprosy, cysticercosis	L24 PH1.16 NSAIDS			P15 PA13.2 Anticoagulant B	P15 PH1.8 drug interaction C	P15 MI1.8,8.15 Ag-Ab reaction A
Thurs 1/7/21	L9 SU5.1,5.2 Wound Healing & care	L24 PA11.1,11.2 genetic disorders of childhood			P18 PA14.3 PBS microcytic A	P18 PH1.8 drug interaction B	P18 MI1.2 stool microscopy C
Fri 2/7/21	AETCOM	L21 MI 2.7 HIV/AIDS			P17 PA13.5 PBS Anaemia C	P17 PH1.8 drug interaction A	P17 MI1.8 Acid fast staining B
Sat 3/7/21	L25 PH1.48 HIV/UTI/STD	L25 PA11.3 storage disorder			P16 PA13.5 PBS Anaemia B	P16 PH1.8 Drug interaction	P16 MI1.2 Acid fast staining

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30 pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 5/7/21	L10 IM2.1,2 ischaemic heart dis	L22 MI1.1 Hyper sensitivity			P19 PBS haemolytic anaemia A	P19 PH1.8 Drug interaction B	P19 MI8.5,8.6,87 healthcare asso inf (sgd) C
Tues 6/7/21	L23 MI1.10 autoimmune	L26 PH1.16 migraine			P18 PA14.3 PBS microcytic anaemia C	P18 PH1.8 drug interaction A	P18 MI1.2 stool microscopy B
Wed 7/7/21	L26 PA12.1,12.2 12.3 PEM, obesity, pollution	L27 PH1.19 sedative anxiolytic			P17 PA13.5 PBS Anaemia B	P17 PH1.8 drug interaction C	P17 MI1.8 Acid fast staining A
Thurs 8/7/21	L10 SU6.1,6.2 surgical infections	L27 PA13.1,13.3, 13.4 hematopoeisi s			P20 PA16.7 cross matching A	P20 PH3.1 Prescriptio n writing B	P20 MI8.7 hand hygeine, ppe C
Fri 9/7/21	L4 FM1.6,7,8 perjury dying declaration	L24 MI1.10 immune disorders			P19 PBS haemolytic anaemia C	P19 PH1.8 Drug interaction A	P19 MI8.5,8.6,87 healthcare asso inf (sgd) B
Sat 10/7/21	L28 PH1.19 antipsychoti c	L28 PA14.1,14.2 microcytic anaemia			P18 PA14.3 PBS anaemia microcytic B	P18 PH1.8 drug interaction C	P18 MI1.2 stool microscopy A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 12/7/21							
Tues 13/7/21	L25 MI1.11 transplant cancer	L29 PH1.16 gout rheumatic			P20 PA16.7 cross matching A	P20 PH3.1 Prescription writing B	P20 MI8.7 hand hygeine, ppe C
Wed 14/7/21	L29 PA15.1,2,3,4 macrocytic anaemia	L30 PH1.19 antidepressants			P19 PBS haemolytic anaemia C	P19 PH1.8 Drug interaction A	P19 MI8.5,8.6,87 healthcare asso inf (sgd) B
Thurs 15/7/21	L11 SU5.1,5.2 Wound Healing & care	L30 PA16.1,16.2 hemolytic anaemia			P21 PA17.2 Bone marrow aspirat A	P21 PH3.1 prescription writing B	P21 MI1.4,1.5 sterilise disinfect C
Fri 16/7/21	A E T C O M	L26 MI1.9 Immuno prophyllaxis			P21 PA17.2 Bone marrow aspirat C	P21 PH3.1 prescription writing A	P21 MI1.4,1.5 sterilise disinfect B
Sat 17/7/21	L31 PH1.19 opioids	L31 PA16.3 thalasaemia sickle cell			P20 PA16.7 cross matching B	P20 PH3.1 Prescription writing C	P20 MI8.7 hand hygeine, ppe A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 19/7/21	L11 IM2.3,4 athero sclerosis complicatn	L27 MI2.1,2.2 endocarditis			P22 PA19.3 TB lymph node A	P22 PH3.1 prescription writing B	P22 MI1.5 CSSD visit C
Tues 20/7/21	L28 MI2.1,2,4 blood infection	L32 antimaniac neuro degeneraive			P22 PA19.3 TB lymph node C	P22 PH3.1 prescription writing A	P22 MI1.5 CSSD visit B
Wed 21/7/21							
Thurs 22/7/21	L12 SU6.1,6.2 surgical infections	L32 PA16.4,5 PBS hemolytic			P23 PA19.5 hodgkins lymphoma A	P23 PH3.1 prescription writing B	P23 MI8.5,8.6 needle stick injury C
Fri 23/7/21	L5 FM1.9,10 medical evidence MCCD	L29 MI3.3 enteric fever			P23 PA19.5 hodgkins lymphoma C	P23 PH3.1 prescription writing A	P23 MI8.5,8.6 needle stick injury B
Sat 24/7/21	L33 PH1.19 antiepileptic PH1.19	L33 PA17.1 aplastic anaemia			P21 PA17.2 Bone marrow aspirat B	P21 PH3.1 prescription writing C	P21 MI1.4,1.5 sterilise disinfect A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 26/7/21	L12 IM2.5 acute coronary syndrome	L6 CM 8.3 National Health Programs			P24 PA19.7 Splenomegaly A	P24 PH3.1 prescription writing B	P24 MI8.7 biomedical wastePPE C
Tues 27/7/21	L30 MI1.1 rickettsial	L34 PH1.20,1.21 ethanol, methanol			P24 PA19.7 Splenomegaly C	P24 PH3.1 prescription writing A	P24 MI8.7 biomedical wastePPE B
Wed 28/7/21	L34 PA18.1 leucopenia cytosis	L35 PH1.22,1.23 drug abuse			P22 PA19.3 TB lymph node B	P22 PH3.1 prescription writing C	P22 MI1.5 CSSD visit A
Thurs 29/7/21	L13 SU7.1,7.2 audit & research	L35 PA18.2 Ac/Chr leukaemia			P25 PA20.1 Plasma cell Myeloma A	P25 PH3.2 Prescriptn Criticism B	P25 MI2.3,8.15 Sepsis,CRBSI C
Fri 30/7/21	AETCOM	L31 MI1.1 haemorrhagic fever viral			P25 PA20.1 Plasma cell Myeloma C	P25 PH3.2 Prescriptn Criticism A	P25 MI2.3,8.15 Sepsis,CRBSI B
Sat 31/7/21	L36 PH1.47 amebiasis antihelminthics	L36 PA19.1,19.2 TB lymphad enopathy			P23 PA19.5 hodgkins lymphoma B	P23 PH3.1 prescription writing C	P23 MI8.5,8.6 needle stick injury A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 2/8/21	PRACTICAL ASSESSMENT (PATHOLOGY)						
Tues 3/8/21	PRACTICAL ASSESSMENT (PHARMACOLOGY)						
Wed 4/8/21	PRACTICAL ASSESSMENT (MICROBIOLOGY)						
Thurs 5/8/21	REVISION CLASSES						
Fri 6/8/21	A E T C O M	REVISION CLASSES					
Sat 7/8/21	THEORY ASSESSMENT						

Practical batch division

batch	A	B	C
Roll no	1-67	68-134	134-200

Colour code for subjects

pathology	pharmacology
microbiology	FSM
medicine	surgery
Community medicine	AETCOM

Clinical posting batch division

Batch	A	B	C	D	E	F
Roll no	1-33	34-66	67-99	100-132	133-165	166-200

Clinical posting schedule for Phase II

	medicine	surgery	gynae & obs	paediatrics	community medicine	chest	Derma & Psychiatry
A	1/5 - 31/5	1/6-30/6	1/7-31/7	1/8-31/8	1/9-30/9	1/10-31/10	1/11-31/11
B	1/11-31/11	1/10-31/10	1/5 - 31/5	1/6-30/6	1/7-31/7	1/8-31/8	1/9-30/9
C	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5	1/6-30/6	1/7-31/7	1/8-31/8
D	1/8-31/8	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5	1/6-30/6	1/7-31/7
E	1/7-31/7	1/8-31/8	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5	1/6-30/6
F	1/6-30/6	1/7-31/7	1/8-31/8	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 9/8/21	L13 IM2.5 treatment of acute coronary syndrome	L32 MI12.5,8.16 Malaria & Babesiosis			P26 PA22.1 Bl grouping 1 A	P26 PH1.20 alcohol poisoning B	P26 MI1.7,8 Hand Hygiene PPE C
Tues 10/8/21	L33 MI12.5,8.1 6 Malaria & Babesiosis	L36 PH1.24 diuretics			P26 PA22.1 Bl grouping 1 C	P26 PH1.20 alcohol poisoning A	P26 MI1.7,8 Hand Hygiene PPE B
Wed 11/8/21	L36 PA19.4 HI&NHL	L37 PH1.24 diuretics			P24 PA19.7 Splénomegaly B	P24 PH3.1 prescription writing C	P24 MI8.7 biomedical wastePPE A
Thurs 12/8/21	L13 SU7.1,7.2 audit & research	L37 PA19.6 splénomega ly			P27 PA22.2 Bl grouping 2 A	P27 PH1.22 Drug abuse B	P27 MI1.4,5 Sterilization & disinfection C
Fri 13/8/21	L6 FM2.1,2,3, 4 Death- Natural & Unnatural	L34 MI12.5, 8.16 Leishmaniasis & Trypanosomi asis			P27 PA22.2 Bl grouping 2 C	P27 PH1.22 Drug abuse A	P27 MI1.4,5 Sterilization & disinfection B
Sat 14/8/21	L38 PH1.25 Antiplatelet fibrinolytic	L38 PA21.1,2,3 Heamorrhagic disorders			P25 PA20.1 Plasma cell Myeloma B	P25 PH3.2 Prescriptn Criticism C	P25 MI2.3,8.15 Sepsis,CRBSI A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 16/8/21	L14 IM2.16,17 thrombolysis, PTCA, CABG in ac coronary syn	L7 CM7.2 Disease transmission prevention control			P28 PA23.1 Urinary examination A	P28 PH3.1 prescription writing B	P28 MI1.5 CSSD visit for sterilization C
Tues 17/8/21	L35 MI2.5,8.16 Lymphatic filariasis	L39 PH1.26 RAAS anticoagulant			P28 PA23.1 Urinary examination C	P28 PH3.1 prescription writing A	P28 MI1.5 CSSD visit for sterilization B
Wed 18/8/21	L39 PA21.4,5 DIC	L40 PH1.25 anticoagulant			P26 PA22.1 Bl grouping 1 B	P26 PH1.20 alcohol poisoning C	P26 MI1.7,8 Hand Hygiene PPE A
Thurs 19/8/21							
Fri 20/8/21	AETCOM	L36 MI3.1 GIT infective syndrome			P29 PA23.2 Body fluids C	P29 PH1.23 De- addiction A	P29 MI8.5,6 Needle stick injury B
Sat 21/8/21	L41 PH1.27 antihyperte nsive	L40 PA22.4,5,6,7 Blood banking & transfusion			P27 PA22.2 Bl grouping 2 B	P27 PH1.22 Drug abuse C	P27 MI1.4,5 Sterilization & disinfection A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 23/8/21	L15 IM2.18,23 dyslipidaemia	L37 MI3.1 Cholera			P29 PA23.2 Body fluids A	P29 PH1.23 De-addiction B	P29 MI8.5,6 Needle stick injury C
Tues 24/8/21	L38 MI3.1 Cholera	L42 PH1.32,1.33 asthma,COPD			P30 PA23.3 Semen analysis + Thyroid function test C	P30 PH1.13 Cholinergic anticholinergic A	P30 MI8.7 Had hygiene PPE,Biomed waste B
Wed 25/8/21	L41 PA24.1,2 Oralcancers Pepticulcer disease	L43 PH1.32,1.33 asthma,COPD			P28 PA23.1 Urinary examination B	P28 PH3.1 prescription writing C	P28 MI1.5 CSSD visit for sterilization A
Thurs 26/8/21	L1 OG2.1 development genital organs	L42 PA24.4 Carcinoma stomach			P30 PA23.3 Semenanalysis + Thyroid function test A	P30 PH1.13 Cholinergic anticholinergic B	P30 MI8.7 Had hygiene PPE,Biomed waste C
Fri 27/8/21	L7 FM2.5,6,7 FM1.11	L39 MI3.1 amoebiasis			P31 PA23.3 LFT + RFT C	P31 PH1.13 adrenergic antiandre A	P31 MI8.7 Had hygiene PPE,Biomed waste B
Sat 28/8/21	L44 PH1.60 Pharmaco Genomics economics	L43 PA24.5 Tuberculosis of intestine			P29 PA23.2 Body fluids B	P29 PH1.23 De-addiction B	P29 MI8.5,6 Needle stick injury C

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 30/8/21							
Tues 31/8/21	L40 MI3.1 helminthiasis	L45 PH1.28 angina			P32 PA24.3 Microscopy- Peptic ulcer C	P32 PH1.32 asthma COPD A	P32 MI8.7 Had hygiene PPE,Biomed waste B
Wed 1/9/21	L44 PA24.6 Inflammatory bowel disease	L46 PH1.28 Angina PVS			P30 PA23.3 Semen analysis + Thyroid function test B	P30 PH1.13 Cholinergic anticholinergic C	P30 MI8.7 Had hygiene PPE,Biomed waste A
Thurs 2/9/21	L2 OG23.1 Normal puberty	L45 PA24.7 Carcinoma of colon			P31 PA23.3 LFT + RFT A	P31 PH1.13 adrenergic antiandrogenic B	P31 MI8.7 Had hygiene PPE,Biomed waste C
Fri 3/9/21	AETCOM	L41 MI3.1 helminthiasis L31			P33 PA25.6 LFT- Interpretation + Viral hepatitis- serology panel C	P33 PH1.33 Antitussive expectorant A	P33 MI2.3,8.15 Sepsis CRBSI, Inf endocarditis B

Sat 4/9/21	L47 PH1.30 Antiarythmic	L46 PA25.1 Bilirubin metabolism, jaundice			P31 PA23.3 LFT + RFT B	P31 PH1.13 adrenergic antiandre C	P31 MI8.7 Had hygiene PPE,Biomed waste A
---------------	-------------------------------	---	--	--	---------------------------------	---	--

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 6/9/21	L16 IM2.19 Complicati on of ACS	L42 MI3.7 Inf syn hepatobiliary			P32 PA24.3 Microscopy- Peptic ulcer A	P32 PH1.32 asthma COPD B	P32 MI8.2 Hand hygiene BMW, PPE C
Tues 7/9/21	L43 MI4.1,2,3 inf syn skin, soft tissue	L48 PH1.29 Congestive HF			P34 PA25.6 Obstructive vs non- obstructive jaundice C	P34 PH3.3 Drug prom tional lit review A	P34 MI8.1 Brucellosis leptospira B
Wed 8/9/21	L47 PA25.2 Hepatic failure	L49 PH1.29 Congestive HF			P32 PA24.3 Microscopy- Peptic ulcer B	P32 PH1.32 asthma COPD C	P32 MI8.2 hand hygiene BMW, PPE A
Thurs 19/9/21	L3 OG23.3 Anormal puberty	L48 PA25.3 Viral Hepatitis			P33, PA25.6 LFT- Interpretatio n + Viral hepatitis- serology panel A	P33 PH1.33 Antitussive expectoran B	P33 MI2.3,8.15 Sepsis CRBSI C

<p>Fri 10/9/21</p>	<p>L8 FM2.8 Signs of death</p>	<p>L44 MI4.3 viral exanthema</p>			<p>P35 PA27.8 Interpretatio n-Acute coronary syndrome C</p>	<p>P35 PH1.34 GERD, Acid peptic dis antiemetic A</p>	<p>P35 MI3.4,8.14 Enteric feve Scrub typhu B</p>
<p>Sat 11/9/21</p>	<p>L50 PH1.31 dyslipidae mia</p>	<p>L49 PA25.4 Alcoholic liver ds & Cirrhosis</p>			<p>P33 PA25.6 LFT- Interpretatio n + Viral hepatitis- serology panel B</p>	<p>P33 PH1.33 Antitussive expectoran C</p>	<p>P33 MI2.3,8.15 Sepsis CRBSI A</p>

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 13/9/21	L17 IM2.20 Pathogenesis management of ACS	L8 CM7.3,7.4 Morbidity Mortality epidemiology			P34, PA25.6 Obstructive vs non- obstructive jaundice A	P34 PH3.3 Drug prom tional lit review B	P34 MI8.1 Brucellosis leptospira C
Tues 14/9/21	L45 MI4.3 viral cutaneous lesion	L51 PH1.34 antidiarhoeal Antiulcer			P36 PA31.3 Ca Breast- morphology & microscopy C	P36 PH1.34 GERD, Acid peptic dis antiemetic A	P36 MI1.2 Gram staining B
Wed 15/9/21	L50 PA25.5 Portal hypertensi on	L52 PH1.34 antiemetic			P34 PA25.6 Obstructive vs non- obstructive jaundice B	P34 PH3.3 Drug prom tional lit review C	P34 MI8.1 Brucellosis leptospira A
Thurs 16/9/21	L4 OG3.1 Menstruati on	L51 PA26.1 Pneumonia			P35 PA27.8 Interpretatio n-Acute coronary syndrome A	P35 PH1.34 GERD, Acid peptic dis antiemetic B	P35 MI3.4,8.14 Enteric feve Scrub typhu C
Fri 17/9/21	AETCOM	L46 MI6.1 Resp tract inf			P37 PA34.4 Tumors of skin C	P37 PH3.5 P DRUG A	P37 MI2.7,8.15 HIV Dengue B

Sat 18/9/21	L53 PH1.34 IBD, laxative	L52 PA26.2 Lung abscess			P35 PA27.8 Interpretation-Acute coronary syndrome B	P35 PH1.34 GERD, Acid peptic, anti emeti C	P35 MI3.4,8.14 Enteric feve Scrub typhu A
----------------	-----------------------------------	-------------------------------	--	--	--	--	---

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 20/9/21	L18 IM3.1.2 Pneumonia microbiology	L47 MI6.1 Bact lobar pneumonia			P36 PA31.3 Ca Breast- morphology & microscopy A	P36 PH1.34 GERD, Acid peptic dis antiemetic B	P36 MI1.2 Gram staining C
Tues 21/9/21	L48 MI6.1,8.16 TB NTM	L54 PH1.44 Anti TB			P38 PA35.3 CSF interpretation C	P38 PH3.5 P DRUG A	P38 MI1.2 Acid fast Stain B
Wed 22/9/21	L53 PA26.3 Obstructive airway ds & bronchiect asis	L55 PH1.45 XDR, MDR TB			P36 PA31.3 Ca Breast- morphology & microscopy B	P36 PH1.34 GERD, Acid peptic dis antiemetic C	P36 MI1.2 Gram staining A
Thurs 23/9/21	L5 OG24.1 Abnormal menstruation	L54 PA26.4 Tuberculosis			P37 PA34.4 Tumors of skin A	P37 PH3.5 P DRUG B	P37 MI2.7,8.15 HIV Dengue C

Fri 24/9/21	L9 FM2.8 Rigor mortis	L49 MI6.1 myxovirus			P39 PA25.6 LFT- Interpretatio n + Viral hepatitis- serology panel C	P39 PH3.7 EML A	P39 MI2.6,8.15 Malaria filaria B
Sat 25/9/21	L56 PH1.36 Thyroid hormones	L55 PA26.5 Occupational lung ds			P37 PA34.4 Tumors of skin B	P37 PH3.5 P DRUG A	P37 MI2.7,8.15 HIV Dengue C

	9-10am	10-11am	11- 1.30 Clinical posting	1.30- 2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 27/9/21	L19 IM3.3 Pneumonia pathogenes is	L9 CM6.1 research question			P38 PA35.3,CSF interpretatio n A	P38 PH3.5 P DRUG B	P38 MI1.2 Acid fast Stain C
Tues 28/9/21	L50 MI6.1 COVID 19 Corona inf	L57 PH1.36 Diabetes mellitus			P40 PA23.3 LFT + RFT C	P40 PH4.1 Drug administer mannequin A	P40 MI1.1h Sys mycosis B
Wed 29/9/21	L56 PA26.6 Tumors of lung & pluera	L58 PH1.36 Diabetes mellitus			P38 PA35.3 CSF interpretatio n B	P38 PH3.5 P DRUG C	P38 MI1.2 Acid fast Stain A

Thurs 30/9/21	L6 OG23.1 Puberty menorrhagia	L57 PA26.7 Mesotheliom a			P39 PA25.6 LFT- Interpretatio n + Viral hepatitis- serology panel A	P39 PH3.7 EML B	P39 MI2.6,8.15 Malaria filaria C
Fri 1/10/21	AETCOM	L51 MI5.1,2 Infective syn CNS			P41 PA27.8 Interpretatio n-Acute coronary syndrome C	P41 PH4.1 Drug administer mannequin A	P41 MI3.5 food poisoning B
Sat 2/10/21							

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 4/10/21	L20 IM3.16,17 Pneumonia supportive therapy	L52 MI5.1 Bacterial meningitis			P40 PA23.3 LFT + RFT A	P40 PH4.1 Drug administer mannequin B	P40 MI1.1h Sys mycosis C
Tues 5/10/21	L53 MI4.1 Tetanus	L59 PH1.38 cortico steroids			P42 PA25.6 Obstructive vs non- obstructive jaundice C	P42 PH4.1 Drug administer mannequin A	P42 MI3.2 Dysentery diarrhoea B
Wed 6/10/21							
Thurs 7/10/21	L7 OG27.1 PID	L58 PA27.1 Arteriosclero sis vs Atheroscleros i			P41 PA27.8 Interpretatio n-Acute coronary syndrome A	P41 PH4.1 Drug administer mannequin B	P41 MI3.5 food poisoning C
Fri 8/10/21	L10 FM2.9.10 Putrifaction ,time since death	L54 MI5.2 Viral encephalitis encepalopath			P43 PA23.3 Semenanalsi s + Thyroid function test C	P43 PH4.2 CAL A	P43 MI1.2 Gram stain B
Sat 9/10/21	L60 PH1.36 Ca metabo lism	L59 PA27.2 Aneurysms			P39 PA25.6 LFT- Interpretatio n + Viral hepatitis- serology	P39 PH3.7 EML C	P39 MI2.6,8.15 Malaria filarial A

					panel B		
--	--	--	--	--	---------	--	--

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 11/10/21							
Tues 12/10/21							
Wed 13/10/21							
Thurs 14/10/21							
Fri 15/10/21							
Sat 16/10/21	L61 PH1.371.41 ant pitutary hormone	L60 PA27.3 Heart Failure			P40 PA23.3 LFT + RFT B	P40 PH4.1 Drug administer mannequin C	P40 MI1.1h Sys mycosis A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 18/10/21							
Tues 19/10/21							
Wed 20/10/21							
Thurs 21/10/21							
Fri 22/10/21							
Sat 23/10/21	L62 PH1.53 Poisoning chelating	L61 PA27.4 Rheumatic fever			P41 PA27.8 Interpretatio n-Acute coronary syndrome B	P41 PH4.1 Drug administer mannequin C	P41 MI3.5 food poisoning A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 25/10/21	L21 IM3.15,17 Ventilation, hospitalization in pneumonia	L10 CM6.2 Statistical data			P42 PA25.6 Obstructive vs non- obstructive jaundice A	P42 PH4.1 Drug administer mannequin B	P42 MI3.2 Dysentery diarrhoea C
Tues 26/10/21	L56 MI7.1,2 Inf syn genital tract	L63 PH1.39 Contracep tion drugs			P44 PA 22.1,2 Blood grp PA16.7 cross matching C	P44 PH4.2 CAL A	P44 MI3.1,6 Misc B
Wed 27/10/21	L62 PA27.5 Ischemic heart disease	L64 PH1.39 Contracep tion drugs			P42 PA25.6 Obstructive vs non- obstructive jaundice B	P42 PH4.1 Drug administer mannequin C	P42 MI3.2 Dysentery diarrhoea A

Thurs 28/10/21	L8 OG21.1 Contraception, IU Device	L63 PA27.6 Infective endocarditis			P43 PA23.3 Semenanalysis + Thyroid function test A	P43 PH4.2 CAL B	P43 MI1.2 Gram stain C
Fri 29/10/21	AETCOM	L57 MI8.5,6 healthcare associated infection			P45 PA19.5 hodgkins lymphoma C	P45 PH4.2 CAL A	P45 MI3.1 Int protozoal Inf B
Sat 30/10/21	L65 Ph1.40 Infertility Erectile dys	L64 PA27.7 Pericarditis & Pericardial effusion			P43 PA23.3 Semenanalysis + Thyroid function test B	P43 PH4.2 CAL C	P43 MI1.2 Gram stain A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 1/11/21	L22 IM3.19 pneumococcal and influenza vaccine	L58 MI1.6 Antimicrobial steward			P44 PA 22.1,2 Blood grp PA16.7 cross matching A	P44 PH4.2 CAL B	P44 MI3.1,6 Misc C
Tues 2/11/21	L59 MI8.3 oncogenic organism	L66 PH1.1 Gout, anti rheumatic			P46 PA20.1 Plasma cell Myeloma C	P46 PH2.3 IV drip setting A	P46 MI1.2, 3.2 Stool micro protozoal B
Wed 3/11/21	L65 PA27.9 Cardiomyo pathies	L67 PH1.35 anaemia			P44 PA 22.1,2 Blood grp PA16.7 cross matching B	P44 PH4.2 CAL C	P44 MI3.1,6 Misc A
Thurs 4/11/21							
Fri 5/11/21							
Sat 6/11/21							

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 8/11/21	L23 IM1.21 acute subacute endocarditis	L11 CM6.3 Frequency distribution			P45 PA19.5 hodgkins lymphoma A	P45 PH4.2 CAL B	P45 MI3.1 Int protozoal Inf C
Tues 9/11/21	L60 MI7.2 Gonococcal NGO	L68 PH1.35 Anaemia, CSF			P47 PA23.1 Urinary examination C	P47 PH3.8 Communica te proper drug use A	P47 MI3.1 int helminth inf B
Wed 10/11/21	L66 PA27.10 Syphilis and the CVS	L69 PH1.46 Antileprotic			P45 PA19.5 hodgkins lymphoma B	P45 PH4.2 CAL C	P45 MI3.1 Int protozoal Inf A
Thurs 11/11/21	L9 OG21.1 Oral contracepti on	L67 PA28.1 Histology of kidney			P46 PA20.1 Plasma cell Myeloma A	P46 PH2.3 IV drip setting B	P46 MI1.2, 3.2 Stool micro protozoal C
Fri 12/11/21	AETCOM	L61 MI UTI lab diagnosis			P48 PA24.3 Microscopy- Peptic ulcer C	P48 PH5.1 Ethics on drug use A	P48 MI1.2 Acid fast staining B
Sat 13/11/21	L70 PH1.49 anticancer	L68 PA28.2 Clinical syndromes of kidney			P46 PA20.1 Plasma cell Myeloma B	P46 PH2.3 IV drip setting C	P46 MI1.2, 3.2 Stool micro protozoal A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 15/11/21							
Tues 16/11/21	L62 MI 7.1,2 STI Lab diagnosis	L71 PH1.49 anticancer			P49 PA31.3 Ca Breast- morphology & microscopy C	P49 PH5.2 Communica te Drug therapy, device storage A	P47 MI3.1 int helminth inf B
Wed 17/11/21	L69 PA28.3 Acute renal failure	L72 PH1.50 organ transplant Reject manag Immuno Modulator			P47 PA23.1 Urinary examination B	P47, PH3.8 Communica te proper drug use C	P49 MI1.2,3.2 stool micro cystode nematode A
Thurs 18/11/21	L10 OG20.1 MTP	L70 PA28.4 Chronic renal failure			P47 PA23.1 Urinary examination A	P47, PH3.8 Communica te proper drug use B	P47 MI3.1 int helminth inf C
Fri 19/11/21							
Sat 20/11/21	L73 PH1.54 vaccines	L71 PA28.5 Glomerular diseases			P48 PA24.3 Microscopy- Peptic ulcer B	P48 PH5.1 Ethics on drug use C	P48 MI1.2 Acid fast staining A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 22/11/21	SDL	L12 CM 6.3 Measures of central tendency and dispersion			P48 PA24.3 Microscopy- Peptic ulcer A	P48 PH5.1 Ethics on drug use B	P48 MI1.2 Acid fast staining C
Tues 23/11/21	L63 MI 8.8 Air, water surface bacteriolog	L74 PH1.47 malaria			SDL1	P50, PH5.3 Motivate adherence To drug A	P50 MI4.3,4.1,8.15,1.2 strepto staph gram stain B
Wed 24/11/21	L72 PA28.6,7,8 IgA nephropathy	L75 PH1.47 Malaria			P49 PA31.3 Ca Breast-morphology & microscopy B	P49, PH5.2 Communicate Drug therapy, device storage C	P49 MI1.2,3.2 stool microcystode nematode A
Thurs 25/11/21	L11 OG21.1 Tubectomy	L73 PA28.9,10 ATN, pyelonephritis			P49 PA31.3 Ca Breast-morphology & microscopy A	P49, PH5.2 Communicate Drug therapy, device storage B	P49 MI1.2,3.2 stool microcystode nematode C
Fri 26/11/21	AETCOM	L64 MI1.1 Congenital inf			SDL2	P51 PH5.4 Drug Cost compliance A	P51 MI6.2 Throat swan gram stain B
Sat 27/11/21	L76 PH1.55 National Health prog	L74 PA28.11,12,13,15 Vascular ds of kidney,cystic ds, renal stones			SDL3	P50, PH5.3 Motivate adherence To drug C	P50 MI4.3,4.1,8.15,1.2 Strepto,staph gram stain A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 29/11/21	P1,CM 7.5 Epidemiological Descriptive study	L65 MI 8.1 Zoonotic inf			SDL4	P50, PH5.3 Motivate adherence To drug B	P50 MI4.3,4.1,8. 15,1.2 Strepto, staph gram stain C
Tues 30/11/21	L66 MI8.2 Oppurtunistic inf	L77 PH1.57,58 skin and ocular drugs			SDL5	P52, PH5.5 Drug dependenc e manage A	P52 MI6.3 Sputum gram stain B
Wed 1/12/21	L75 PA28.14,16 Tumors of kidney	L78 PH1.59 OTC FDC, EML, herbal			SDL6	P51 PH5.4 Drug Cost compliance C	P51 MI6.2 Throat swab gram stain A
Thurs 2/12/21	L12 OG1.1,2 Maternal Perinatal mortality	L76 PA29.1,2 Testicular tumors, Ca Penis			SDL7	P51 PH5.4 Drug Cost compliance B	P51 MI6.2 Throat swab gram stain C
Fri 3/12/21	L11 FM2.11,12, 13,14,15	L67 MI 8.4 Emerging Reemerging inf			SDL8	P53, PH5.5 OTC, Drug dependenc A	P53 Mi6.3 1.2 Sputum acid fast stain B

Sat 4/12/21	L79 PH1.61 Nutraceutic Dietary supplemnt	L77 PA29.3,4,5 BPH, Prostate ca, Prostatitis			SDL9	P52, PH5.5 Drug dependenc e manage C	P52 MI6.3 Sputum gram stain A
----------------	--	---	--	--	------	--	---

	9-10am	10-11am	11- 1.30 Clinical posting	1.30- 2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM

Mon 6/12/21	ASSESSMENT						
Tues 7/12/21	ASSESSMENT						
Wed 8/12/21	ASSESSMENT						
Thurs 9/12/21	ASSESSMENT						
Fri 10/12/21	ASSESSMENT						
Sat 11/12/21	ASSESSMENT						

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 13/12/21	P2 CM 7.5 Epidemiological study Descriptive	L68 MI8.4 Bioterrorism agents			SDL10	P52, PH5.5 Drug dependence manage B	P52 MI6.3 Sputum gram stain C
Tues 14/12/21	L69 MI8.5 healthcare asso inf	L80 PH1.64 clinical trials			L PA25.3 Viral Hepatitis	P54, PH5.7 legal ethical aspect of prescriptn A	P54 MI5.3, 8.15,1.2 pyogenic meningitis lab diag B
Wed 15/12/21	L78 PA29.3,4,5 BPH, Prostate ca, Prostatitis	L81 PH1.64 GCP			L PA27.5 IHD	P53, PH5.5 OTC, Drug dependence C	P53 Mi6.3 1.2 Sputum acid fast stain A
Thurs 16/12/21	L13 OG21.1 population control	L79 PA30.1,6 Ca Cervix, cervicitis			L PA28.2 Kidney-syndromes	P53, PH5.5 OTC, Drug dependence B	P53 Mi6.3 1.2 Sputum acid fast stain C
Fri 17/12/21	L12 FM2.16,17,18,19	L70 MI8.16 Cmunicable dis NHP			L PA28.5 GN	P55, PH3.6 interaction with representative A	P55 MI7.2 inf syn genital tract B
Sat 18/12/21	L82 PH1.63 Legalaspect Drug regulatn	L80 PA30.7,8,9 Ca Cervix, cervicitis			L PA28.6 IgA Nephropathy	P54, PH5.7 legal ethical aspect of prescriptn C	P54 MI5.3, 8.15,1.2 pyogenic meningitis lab diag A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 20/12/21	P3 CM 7.5 Epidemiological Cohort Study	L13 CM 7.7 epidemic of communicable disease			L PA30.4 Ovarian tumors	P54, PH5.7 legal ethical aspect of prescrip ⁿ B	P54 MI5.3, 8.15,1.2 pyogenic meningitis lab diag C
Tues 21/12/21	L71 MI 8.5 inf control basics	L83 PH1.51,52 1.62 adulterant, pesticide, anti septic, poisoning			L PA30.5 GTD	P56 P1.4 ADME A	P56 MI8.11 respect pat sample B
Wed 22/12/21	L81 PA30.2,3 CA Endometrium, leiomyoma, leiomyosarcomas	PH1.51,51,1.62 SDL 1			L PA32.1 Iodine dependent thyroid swelling	P55, PH3.6 interaction with representative C	P55 MI7.2 inf syn genital tract A
Thurs 23/12/21	L14 OG27.3 Pelvic infection	L82 PA30.4,5 Ovarian tumors, GTDs			PA32.2,3 Thyrotoxicosis + hypothyroidism	P55, PH3.6 interaction with representative B	P55 MI7.2 inf syn genital tract C
Fri 24/12/21	AETCOM	L14, CM 3.6, 3.7 vectors in the causation of diseases, life cycles, Public Health control measure			PA32.4 Diabetes mellitus	P57 P1.4 ADME A	P57, MI8.14 patient identity confidentiality B
Sat 25/12/21							

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 27/12/21	P4 CM 7.5 Epidemiological Study Experimental	L15 CM 14.1, 14.2 , 14.3hospital waste management			PA32.5,6 Hyperparathyroidism, pancreatic ca	P56 P1.4 ADME B	P56 MI8.11 respect pat sample C
Tues 28/12/21	SDL1	SDL 2			PA32.7,8,9 Adrenal insufficiency, Cushing's syndrome, Adrenal neoplasm	P58 PH1.5 Mechanism of drug action A	B
Wed 29/12/21	L83 PA31.1 Benign breast ds	SDL 3			SDL11	P56 P1.4 ADME C	P56 MI8.11 respect pat sample A
Thurs 30/12/21	L15 OG 22.1 Abnormal vaginal discharge	L84 PA31.2 Ca Breast + Gynecomasti a			SDL12	P57 P1.4 ADME B	P57,MI8.14 patient identity confidentiall ity C
Fri 31/12/21	L13 FM2.24	L16 CM 8.3 National Health Program			SDL13	P59 PH1.5 Mechanism of drug action A	B

Sat 1/1/22	
---------------	--

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 3/1/22	P5 CM 7.7 Investigation of epidemic of communi cable disease	L17 CM6.4 statistical methods including test of significance in various study			SDL14	P58 P58 PH1.5 Mechanism of drug action A B	P1 FM3.1 (Corpus delicti, Identification from Race, Sex, Religion, Stature, Complexion) C
Tues 4/1/22	SDL2	L18 CM 8.3 National Health Programs Tuberculosis			SDL15	P60 PH4.2 CAL A	P1 FM3.1 (Corpus delicti, Identification from Race, Sex, Religion, Stature, Complexion) B
Wed 5/1/22	L85 PA32.1 iodine dependency of thyroid swellings	L83 PH1.44, 1.45 TB, XDR, MDR			SDL16	P57 P1.4 ADME C	P1 FM3.1 (Corpus delicti, Identification from Race, Sex, Religion, Stature, Complexion) A
Thurs 6/1/22	L16 OG4.4 Placenta Amniotic fluid	L86 PA32.2,3 Thyrotoxicosi s + hypothyroidis m			SDL17	P59 PH1.5 Mechanism of drug action B	P2 FM3.1(Skull, Mandible, Sternum) C

Fri 7/1/22	AETCOM	SDL3			SDL18	P61 PH4.2 CAL A	P2 FM3.1 (Skull, Mandible, Sternum) B
Sat 8/1/22	L36 PH1.44, 1.45 SDL 4	L87 PA32.4 Diabetes mellitus			SDL19	P58 P58 PH1.5 Mechanism of drug action A C	P2 FM3.1 (Skull, Mandible, Sternum) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 10/1/22	P6 CM 7.6 need of screening test	SDL4			P60 A	P60 PH4.2 CAL B	P3 FM3.1(Pelvis, Sacrum) C
Tues 11/1/22	SDL5	L19 CM 3.6, CM 8.3 NHP National Vector Borne Disease Control Programme			SDL20	P62 PH4.1Drug administratn mannequin A	P3 FM3.1(Pelvis, Sacrum) B
Wed 12/1/22	L36	L37			P24 B	P24 C	P3 FM3.1(Pelvis, Sacrum) A
Thurs 13/1/22	L17 OG17.1 lactation physiology	L88 PA32.5,6 Hyperparathy roidism, pancreatic ca			SDL21	P61 PH4.2 CAL B	P4 FM3.1(Teeth) C
Fri 14/1/22	L14 FM2.25	SDL6			SDL22	P63 PH4.1Drug administratn mannequin A	P4 FM3.1(Teeth) B
Sat 15/1/22	L84 PH1.47 malaria, kalazar, amoebiasis, helminth	L89 PA32.7,8,9 Adrenal insufficiency, Cushing's syndrome, Adrenal neoplasm			SDL23	P59 PH1.5 Mechanism of drug action C	P4 FM3.1(Teeth) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 17/1/22	P8 CM 7.8 Principles of association, causation and biases in epidemiologi cal study	L20 CM 8.3 NHP including their prevention and treatment of a case : NPCDC			SDL24	P62 PH4.1Drug administratn mannequin B	P5 FM3.1 (Radiography & Age estimation) C
Tues 18/1/22	SDL7	SDL5 PH1.47 malaria, kalazar			SDL25	P64 Ph2.2, ORS prepare A	P5 FM3.1 (Radiography & Age estimation) B
Wed 19/1/22	L90 PA33.1,2 Osteomyeli tis, Bone tumors	SDL 6			SDL26	P60 PH4.2 CAL C	P5 FM3.1 (Radiography & Age estimation) A
Thurs 20/1/22	L18 OG2.1 Female pelvis	L91 PA33.3,4 Soft tissue tumors, Paget's ds			SDL27	P63 PH4.1Drug administratn mannequin B	P6 FM3.2 (Hair, Dactylograph y) C
Fri 21/1/22	AETCOM	SDL8			SDL28	P65 PH2.3 IN drip set A	P6 FM3.2 (Hair, Dactylograph y) B

Sat 22/1/22	SDL 7	L92 PA33.5 Rheumatoid arthritis			SDL29	P61 PH4.2 CAL C	P6 FM3.2(Hair, Dactylograph y) A
----------------	-------	--	--	--	-------	--------------------------	--

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 24/1/22	P9 CM 7.9 Application of computers in Epi demiology	SDL9			PA33.5 Rheumatoid arthritis	P64 Ph2.2, ORS prepare B	P7 FM3.2(Tattoo , Scars, Footprints, Superimpositi on) C
Tues 25/1/22	SDL10	SDL8			PA34.1 SCC	P66 PH2.4 dose calculation A	P7 FM3.2(Tattoo , Scars, Footprints, Superimpositi on) B
Wed 26/1/22	L36	L37			P24 B	P24 C	P7 FM3.2(Tattoo , Scars, Footprints, Superimpositi on) A
Thurs 27/1/22	L19 OG2.1 Anatomy reproductive organ	L93 PA34.1 SCC			PA34.2 BCC	P65 PH2.3 IN drip set B	P8 FM3.3(Abrasi on, Bruise) C
Fri 28/1/22	L15 FM2.25	L34			PA34. 3 Melanoma	P67 PH3.4 ADR reporting	P8 FM3.3(Abrasi on, Bruise) B
Sat 29/1/22	SDL9	L94 PA34.2 BCC			PA34. 3 Melanoma	P62 PH4.1Drug administratn mannequin C	P8 FM3.3(Abrasi on, Bruise) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 31/1/22	P10 CM10.5 Universal Immunization Program	L6 CM7.2			SDL	P66 PH2.4dose calculation B	P9 FM3.3 (Laceration, Incised) C
Tues 1/2/22	L30	SDL 10			SDL	P68 PH3.2 Prescription audit A	P9 FM3.3 (Laceration, Incised) B
Wed 2/2/22	L95 PA34. 3 Melanoma	P11 CM 3.8 Commonly used insecticides and rodenticide			SDL	P63 PH4.1Drug administratn mannequin C	P9 FM3.3 (Laceration, Incised) A
Thurs 3/2/22	L20 OG80.3 Placenta and fetal circulation	L96 PA35.1,2 CSF findings + CNS tumors			SDL	P67 PH3.4 ADR reporting B	P10 FM3.3 (Stab, Chop, Defense, Fabricated) C
Fri 4/2/22	AETCOM	L31			SDL	P69 PH3.1 prescription criticism A	P10 FM3.3 (Stab, Chop, Defense, Fabricated) B
Sat 5/2/22	L21 OG6.1 pregnancy diagnosis	L97 PA36.1 Retinoblastoma			SDL	P64 Ph2.2, ORS prepare C	P10 FM3.3 (Stab, Chop, Defense, Fabricated) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 7/2/22	L21 OG7.1 physiological changes in pregnancy	P12 CM 19.1, 19.2, 19.3 EML, counterfeit medicine and its prevention			SDL	P68 PH3.2 Prescription audit B	P11 ✓ FM2.2 0(Defi ne & Classif y Mecha nical Asphy xia) FM2.21 (Hanging) C
Tues 8/2/22	L33	SDL11			SDL	A	P11 ✓ FM2.2 0(Defi ne & Classif y Mecha nical Asphy xia) FM2.21 (Hanging) B
Wed 9/2/22	SDL	SDL12			SDL	P65 PH2.3 IN drip set C	P11 ✓ FM2.2 0(Defi ne & Classif y Mecha nical Asphy xia) FM2.21 (Hanging) A

Thurs 10/2/22	L22 OG7.1 physiological changes in pregnancy	SDL			SDL	P69 PH3.1 prescription criticism B	P12 ✓ FM2.2 1 (Stra ngulati on) FM2.22 (Traumatic asphyxia/ Suffocation/ Sexual asphyxia) C
Fri 11/2/22	L6	P13 CM8.1 laboratory tests at the primary care level for communicable disease			SDL	P27 A	P12 ✓ FM2.2 1 (Stra ngulati on) FM2.22 (Traumatic asphyxia/ Suffocation/ Sexual asphyxia) B
Sat 12/2/22	L23 OG 2.1 nerve , blood supply of pelvic organ	P14 CM 3.6, 3.7 life cycles of vectors of Public Health control measures			SDL	P66, P67 PH2.4dose calculation PH3.4 ADR reporting C	P12 ✓ FM2.2 1 (Stra ngulati on) FM2.22 (Traumatic asphyxia/ Suffocation/ Sexual asphyxia) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon 14/2/22	L12	P15 CM 5.7 Food hygiene			SDL	P24 B	P13 FM2.23 (Drowning) C
Tues 15/2/22	L30	L24 OG3.1 fertilization			SDL	P24 A	P13 FM2.23 (Drowning) B
Wed 16/2/22							
Thurs 17/2/22							
Fri 18/2/22	AETCOM	P16 CM 3.3 the aetiology and basis of water borne disease			SDL	P25 A	P14 ✓ FM2.2 9 (Demo nstrate record of eviden ce in Courts by <i>Role Play</i>) FM2.30 (Knowledge about Government/ Court notifications of MLI) B

Sat 19/2/22	L25 OG17.1 lactation physiology	SDL			SDL	P 68,69 PH3.2 Prescription Audit criticism C	P13 FM2.23 (Drowning) A
----------------	--	-----	--	--	-----	---	----------------------------------

	9-10am	10-11am	11- 1.30 Clinical posting	1.30- 2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM

Mon 21/2/22	ASSESSMENT						
----------------	------------	--	--	--	--	--	--

Tues 22/2/22	ASSESSMENT						
-----------------	------------	--	--	--	--	--	--

Wed 23/2/22	ASSESSMENT						
----------------	------------	--	--	--	--	--	--

Thurs 24/2/22	ASSESSMENT						
------------------	------------	--	--	--	--	--	--

Fri 25/2/22	ASSESSMENT
Sat 26/2/22	ASSESSMENT

